Pilot Study With GFT505 (80mg) in Patients With Insulin Resistance and Abdominal Obesity

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

22 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-01-31

Study Completion Date

2011-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to demonstrate the efficacy on insulin sensitivity of GFT505 at 80mg/d in male patients with insulin resistance and abdominal obesity. Evaluation will be made using a glucose clamp technique.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pilot Study With GFT505 (80mg) in Patients Presenting With Impaired Glucose Tolerance and Abdominal Obesity.

NCT01275469

Impaired Glucose Tolerance Abdominal Obesity

COMPLETED PHASE2

A 12-WEEK TITRATE STUDY TO EVALUATE SAFETY, TOLERABILITY AND PHARMACODYNAMICS OF PF-06882961 IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND IN NON-DIABETIC ADULTS WITH OBESITY

NCT04617275

Diabetes Obesity

COMPLETED PHASE2

To Investigate the Safety, Tolerability and Pharmacodynamics of GSK2890457 in Healthy Volunteers and Subjects With Type 2 Diabetes

NCT01725126

Obesity

COMPLETED PHASE2

Study of INT-747 in Patients With Diabetes and Presumed NAFLD

NCT00501592

Diabetes Mellitus, Type II Fatty Liver

COMPLETED PHASE2

A Multiple Dose Investigational Drug Study in Patients With Type 2 Diabetes (MK-0941-005)

NCT00511667

Type 2 Diabetes Mellitus

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study period per patient is 26 weeks: a selection period will precede a 8-week treatment period, a 6-week wash out period, a second 8-week treatment period in the second arm of treatment and a 2- week follow-up period.

Schedule:

* Selection visit prior to treatment period (D-14 and D-1)
* D0 : randomisation visit
* Period T1: first period of treatment with GFT505 80mg or placebo for 8 weeks (D1 to D56)
* Wash out period for 6 weeks (D57 to D98)
* Period T2: second period of treatment with GFT505 80mg or placebo for 8 weeks (D99 to D154)
* Follow up period for 2 weeks (D155 to D169)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Insulin Resistance Abdominal Obesity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

GFT505 80mg

Group Type EXPERIMENTAL

GFT505 80mg

Intervention Type DRUG

hard gelatin capsules dosed at 20mg, oral administration, 4 capsules per day before breakfast

Matching placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

hard gelatin capsules, oral administration, 4 capsules per day before breakfast

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

GFT505 80mg

hard gelatin capsules dosed at 20mg, oral administration, 4 capsules per day before breakfast

Intervention Type DRUG

Placebo

hard gelatin capsules, oral administration, 4 capsules per day before breakfast

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Waist circumference ≥94cm.
* Body Mass Index ≤ 45kg/m2.
* Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) \> 3.

Exclusion Criteria

* Blood Pressure \> 160 / 95 mmHg.
* Diabetes mellitus 1 or 2.
* Historical of bariatric surgery.
* Patient treated with a lipid-decreasing medication.
* A fasting plasma triglycerides concentration \> 400mg/dL or a plasma Low Density Lipoprotein Cholesterol (LDL-c)concentration \> 220mg/dL.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No